Ira Klein, MD, Discusses Quality Measures in Oncology
Ira Klein, MD, MBA, FACP, Chief Medical Officer, National Accounts Clinical Sales & Strategy, Aetna, addresses measurement programs used in oncology. Dr. Klein says that measurement is a driver for value and healthcare in the future. Quality measures like QOPI and HEDIS allow oncologists to measure how they should be rewarded and recognized for making improvement.
This video was taken on November 16 at AJMC's Translating Evidence-Based Research Into Value-Based Decisions in Oncology.
The annual report was published in the March 30 issue of the Journal of the National Cancer Institute. The report was co-authored by experts from the North American Association of Central Cancer Registries, the American Cancer Society, CDC, and the National Cancer Institute.
Knowledge is power, as was the case with a doctoral student at MIT whose keen interest in his own medical data resulted in the diagnosis and excision of a brain tumor. But are all health systems ready to share patients' data with them?
Research published by a team of Italian scientists in the Journal of the National Institute of Cancer shows that a 13-gene panel blood test for microRNAs could be a cost-effective screening tool for lung cancer, compared with low-dose CT, which is expensive.
Hospitals like Boston Children's and Penn Medicine think they are better off building in-house apps that are custom-made for their workflow, rather than risk buying those available in the market, which may not necessarily be a perfect fit.